Compare Amgen, Inc. (AMGN) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Chipotle Mexican Grill, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Chipotle Mexican Grill, Inc. trades at $35.35 (market cap $45.22B). The key difference: Amgen, Inc. is far larger — about 4.3× Chipotle Mexican Grill, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | CMG | |
|---|---|---|
Market Cap | $196.12B | $45.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $56.00 |
52-Week Low | $271.18 | $28.17 |
Enterprise Value | $241.41B | $49.59B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Chipotle Mexican Grill (CMG) trades at $35.25, up 1.88% on the day, with strong analyst support and consistent earnings beats. The stock shows bullish technical signals with support at $34 and resistance at $35. Revenue grew to $11.93 billion in 2025, with a net income margin of 11.96%, though margins have narrowed slightly from prior years. Recent news highlights operational focus and menu innovation as growth drivers.
Outlook remains positive with a $40.46 consensus price target, but risks include cost pressures and competitive threats. The stock offers growth potential through expansion and operational excellence, yet investors should monitor margin trends and consumer spending shifts in the volatile restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
